Skip to content

Telix Pharmaceuticals

US · TLX #2345 by market cap Listed 2024
8.37 -0.34 -3.90%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 8.40 -3.56%
After-hours 8.37 0.00%
Overnight 8.52 -2.18%
12.838.378.372026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on TLX?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -18.6% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2849 U.S. stocks StockVane covers.

Last computed: 2026-11-21 14:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall C-

The radar needs all six factors. Available grades are shown below.

Valuation D+

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 86.3x Better than 5%
Forward P/E 312.5x Better than 1%
Price / Sales 3.5x Better than 35%
P/E vs own 5-yr range 40th pctl Better than 69%
Growth A+

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 94.7% Better than 98%
Free cash flow CAGR (3Y) 78.5% Better than 90%
Profitability C

How much profit the business keeps from each dollar of sales and capital.

Gross margin 53.1% Better than 67%
Operating margin 2.2% Better than 26%
Net margin -0.9% Better than 24%
Return on equity -1.9% Better than 26%
Return on invested capital 2.1% Better than 34%
Momentum C

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -26.1% Better than 22%
6-month return -11.6% Better than 37%
12-month return (ex latest month) 7.1% Better than 42%
Distance below 52-week high 36.2% Better than 33%
Financial Health D-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 1.4x Better than 38%
Debt to assets 40.1% Better than 27%
Interest coverage 0.9x Better than 28%
Free cash flow / net income 18.0% Better than 5%
Analyst View N/A

What the Street thinks: share of Buy ratings and upside to the average target.

Not enough data to grade this factor.

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -9.32%
1M -25.00%
3M -32.61%
6M -18.58%
YTD +11.75%
1Y -4.56%

Key statistics

Price & volume

Prev close
8.71
Open
8.66
Day range
8.37 - 8.70
Avg price
8.48
Volume
269.43K
Turnover
2.29M
Amplitude
3.85%
52-week range
6.28 - 13.11

Valuation

P/E
-398.57
P/E (TTM)
86.29
P/B
6.83
EPS
-0.02
Net profit
-7.11M
Net assets
415.34M

Share structure

Market cap
2.84B
Float cap
2.27B
Shares out
338.78M
Float shares
271.65M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2024-11-14
52-week range 31% of range
6.28 13.11

36.2% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-815.49K net over the window

Short interest

Shares short
270.62K
As of
2026-10-30

Frequently asked questions

What is the current stock price of Telix Pharmaceuticals (TLX)?

Telix Pharmaceuticals last traded at 8.37. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Telix Pharmaceuticals's market cap?

About 2.84B.

What is the P/E ratio of Telix Pharmaceuticals?

The trailing twelve-month P/E is 86.29, above its own 5-year average of 40.89 — in the middle of its historical range (39.74% percentile). See the Valuation tab for the full history.

Does Telix Pharmaceuticals pay a dividend?

Telix Pharmaceuticals does not currently pay a regular dividend.

Is Telix Pharmaceuticals a buy according to analysts?

The consensus of 2 analysts is a Buy rating, with an average 12-month price target of 20.00, which implies 138.9% upside from the current price. This is not investment advice.

What is Telix Pharmaceuticals's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Telix Pharmaceuticals a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Telix Pharmaceuticals discussion 0 comments

Add a comment